Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Phase IIIb Clinical Study to Evaluate the Long-term Safety and Efficacy of WS016 in Patients With Hyperkalemia

NCT07881965 is registered in ClinicalTrials.gov with Waterstone Pharmaceutical (Wuhan) Co., LTD. as lead sponsor.

NCT NCT07881965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07881965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Phase IIIb Clinical Study to Evaluate the Long-term Safety and Efficacy of WS016 in Patients With Hyperkalemia
Lead sponsor
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase
Phase 3
Overall status
Recruiting
Start date
September 25, 2026
Completion date
March 30, 2029
Enrollment
300 (estimated)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

hyperkalemia